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In developed countries, infective endocarditis (IE) frequently 
complicates intravenous drug use (IDU) and HIV infection.[1] IE 
due to IDU has been rare in sub-Saharan Africa in both the pre- and 
post-HIV eras, probably owing to the low frequency of IDU.[1] We 
have recently observed an increase in the number of patients with IE 
secondary to intravenous (IV) nyaope use presenting to Chris Hani 
Baragwanath Academic Hospital (CHBAH) in Johannesburg, South 
Africa (SA).[2] Nyaope, also called whoonga (or wunga), is a drug sold 
on the streets and has been in widespread use in SA since about 2010, 
initially among poor communities in Durban.[3] The ingredients are 
not exact or constant, but it usually contains an antiretroviral (ARV) 
such as efavirenz or ritonavir.[3] Other components include heroin, 
crystal methamphetamine, cannabis, cocaine and even rat poison. [3] 
Heroin is the primary substance of abuse for 8% of individuals in 
treatment centres in Gauteng Province, SA. Nyaope is the most 
common form in which heroin is used by black South Africans, 
mainly owing to its low cost. Users become addicted to the heroin 
component, but the neurological effects of efavirenz may play a role, 
as it is known to cause psychoactive symptoms.[3] ARVs may also 
potentiate the hypnotic effects of the other ingredients.[3] ARVs are 
sourced illegally from healthcare workers or are stolen from patients 
taking them.[3] Misuse of ARVs in turn may cause the emergence of 
resistant HIV strains.[3]
Nyaope is exclusive to SA and its use is common among young and 
unemployed black people from poor socioeconomic backgrounds. [3,4] 
Although nyaope was initially smoked, it is now being injected. This 
new pattern of use is likely to lead to an increase in cases of IE.[2]
Objectives
There is a paucity of data on IE secondary to IDU in Africa. Our 
objective was therefore to systematically document the clinical and 
echocardiographic profile of these patients.
Methods
This study of a retrospective case series of patients with IE secondary 
to IV nyaope use was conducted at CHBAH, which serves the 
periurban community of Soweto and is a large tertiary referral 
centre for surrounding hospitals and clinics in Gauteng and adjacent 
provinces. Data on all patients who presented to the cardiology clinic 
with IE secondary to IV nyaope use between December 2014 and 
February 2017 were extracted from hospital records. We included 
all patients aged ≥18 years with documented definite or possible IE 
based on the modified Dukes criteria and a history of IV nyaope use. 
IE cases not related to IV nyaope use were excluded from the study. 
Data were collected by manual review of patient files. The following 
information was collected: patient demographics, comorbidities, 
history of IV nyaope use and its duration, factors predisposing to IE, 
echocardiographic findings, IE-related complications and causative 
micro-organisms, as well as outcomes (death, surgery, medical cure) 
until hospital discharge.
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Background. We have recently noted a dramatic rise in the number of patients with infective endocarditis (IE) related to intravenous (IV) 
nyaope (a mixture of heroin, cocaine and antiretroviral drugs) presenting to Chris Hani Baragwanath Academic Hospital in Johannesburg, 
South Africa.
Objectives. To document the clinical and echocardiographic characteristics of these patients.
Methods. Clinical and echocardiographic characteristics of all patients (N=68) with IE due to IV nyaope use were retrospectively extracted 
from hospital records (December 2014 - February 2017).
Results. The mean (standard deviation) age of the patients was 25.8 (4.5) years (97.1% were male). Withdrawal symptoms were noted in 
25.1% of cases, fever in 58.8%, dyspnoea in 86.7% and right ventricular failure in 42.6%. Most patients were HIV-positive (76.1%), with CD4+ 
cell counts of <200 cells/µL in 8.8% of the total, 58.1% had hepatitis C infection, and only three were on antiretrovirals. Septic pulmonary 
emboli were noted in 61.8%. Blood cultures revealed Staphylococcus aureus in 61.2%, Enterococcus faecalis in 8.8% and Pseudomonas 
aeruginosa in 1 patient; 29.2% had sterile cultures and 8.8% polymicrobial infection. Severe right ventricular systolic dysfunction (RVS' 
Doppler velocity <10 cm/s) and pulmonary hypertension were noted in 19.1% and 62.2% of patients, respectively. Pericardial effusion was 
noted in 37.8%. The most commonly involved valve was the tricuspid (60.1%), followed by the mitral (17.2%), aortic (2.9%) and pulmonary 
(1 patient) valves. Combined valve lesions were noted in 19.1% of patients. Ten patients (14.7%) died. The main predictor of in-hospital 
mortality was S. aureus infection (odds ratio 5.0; p=0.042).
Conclusions. We have documented the common clinical and echocardiographic characteristics of patients with IE secondary to IV nyaope 
use. IE due to IV drug use is responsible for considerable morbidity and mortality in a predominantly young male population.
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The study was approved by the University of 
the Witwatersrand Ethics Committee (ref. 
no. M160723).
Statistical analysis
Statistical analysis was performed with Stati-
stica (version 12.5, series 0414 for Windows; 
Dell, USA). Continuous variables were 
expressed as means (standard deviations 
(SDs)) for normally distributed data or 
medians with interquartile ranges (IQRs) for 
non-parametric data. Categorical variables 
were expressed as percentages and Fisher’s 
exact test was used to compare categorical 
variables. Multivariate analysis was performed 
using logistic regression with statistically or 
clinically significant variables from univariate 
analysis. The level of statistical significance 
was p<0.05. Additionally, clinically significant 
variables with a p-value <0.2 such as age 
≥30 years, pulmonary artery systolic pressure 
≥35 mmHg, right ventricular systolic function 
(RVS') and infection by the most commonly 
encountered pathogen, Staphylococcus aureus, 
were included in the multivariate analysis.
Results
Patient characteristics
The main demographic and clinical charac-
teristics are presented in Table 1. Most patients 
were HIV-positive (76.1%) and not on ARV 
therapy (only three patients were on ARVs 
at presentation). Hepatitis B infection was 
present in 8.2% and hepatitis C infection in 
58.1%. Two  patients (2.9%) required dialysis 
for renal failure.
The most important modes of clinical 
presen tation are depicted in Fig. 1. In 
addi tion,  nonspecific complaints such  as 
headache, chest pain and cough were present 
in 2.1%, 31.2% and 57.4% of patients, 
respec tively. The mean (SD) haemoglobin 
concentration was 9.4 (2.2) g/dL, the mean 
(SD) white cell count 14.4 (7) × 109/L and 
the median platelet count 202.5 × 109/L 
(IQR 138.5 - 365.5). The median C-reactive 
protein level was elevated at 108.5 mg/L 
(IQR 54.5 - 205.0). The median CD4+ count 
was 437 cells/ µL (IQR 266 - 635). Only 8.8% 
of patients had a CD4+ count <200 cells/µL. 
Systemic emboli (central nervous system and 
coronary artery embolisation) were noted in 
11.8% (n=8) of the patients. Septic pulmon ary 
emboli (Fig. 2) were noted in 61.8% (n=42). 
Additional pulmonary involve ment occurred 
in the form of atelectasis, effusion, bullae, 
pneumothorax, alveolar infiltrates, cavitation 
and infarction. Prior antibiotic use before 
the diagnosis of IE was made was reported 
in 60.3% of the patients; 17.1% of these were 
erroneously treated for pneumonia before 
the diagnosis of IE. Pulmonary tuberculosis 
(PTB) was diagnosed in 36.3% of the patients, 
and two patients had coexisting systemic 
hypertension.
Microbiological characteristics
The most common micro-organisms cul-
tured are shown in Fig. 3.
Echocardiographic characteristics
The median left ventricular ejection fraction 
(LVEF) was 64% (IQR 55 - 68%). Seven 
patients had an LVEF of <50%. The right 
ventricle (RV) was enlarged in 59.1% of the 
patients, with a mean (SD) RVS' Doppler 
velocity of 14.2 (4.5) cm/s. Severe RV systolic 
dysfunction was noted in 13 patients (RVS' 
Doppler velocity <10  cm/s). The median 
pulmonary artery systolic pressure (PASP) 
was 35 mmHg (IQR 23 - 42). Pulmonary 
hypertension (PHT) (PASP ≥35 mmHg) was 
present in 62.2% of the patients (Fig. 4). 
The mean (SD) vegetation size was 14.6 
(7.7)  mm. In 20 patients the vegetation 
measured <10  mm. Twenty-five patients 
(37.8%) had pericardial effusion. The most 
commonly involved valve was the tricuspid 
valve (TV) (60.1%), followed by the mitral 
valve (17.2%) and the aortic valve (AV) 
(2.9%) (Fig. 5). The pulmonary valve was 
involved in only 1 patient. Combined 
valve lesions were noted in 19.1% of the 
patients. Severe tricuspid regurgitation (TR) 
was noted in 34 patients (50.0%) (Fig. 4), 
moderate TR in 15 (22.1%) and mild to 
trivial TR in the remaining 19 (27.9%). 
Severe mitral regurgitation (MR) was noted 
in 8 patients (11.7%) and moderate MR in 
3 (4.4%). Severe aortic regurgitation was 
present in 3  patients (4.4%). Underlying 
rheumatic heart disease of the mitral 
valve was noted in 2 patients (2.9%) and 
myxomatous disease was present in 1. Less 
common sites included mural vegetations 
involving the right and left atrial walls 
in 3.0% of the patients, right ventricular 
outflow tract vegetations in 1 patient, isolated 
involvement of TV subvalvular apparatus in 
1, a vegetation on the aortomitral curtain 
in 1 and a periaortic root abscess as a 
complication in 2.
Follow-up and 
in-hospital mortality
On in-hospital follow-up, it was discovered 
that 10 patients (14.7%) had died and 4 
(5.8%) had absconded. Four patients 
under went surgery; 1 underwent tricuspid 
valvulectomy, 1 mitral valve replacement, 
1 TV replacement and 1 AV replacement. 
The remainder of the patients responded to 
Table 1. Demographic and clinical characteristics of patients (N=68) with infective 
endocarditis due to intravenous nyaope use
Age (years), mean (SD) 25.8 (4.5)
Male gender, % 97.1 
Level of education, mean Grade 10
Employed None
Duration of drug use (months), median (IQR) 48 (24 - 72)
NYHA functional class (I/II - III/IV), % 12.6/80.2/7.3 
Systolic blood pressure (mmHg), mean (SD) 113.9 (14.8)
Diastolic blood pressure (mmHg), mean (SD) 68.7 (11.2)
Pulse rate (bpm), mean (SD) 104.3 (22.0)
SD = standard deviation; IQR = interquartile range; NYHA = New York Heart Association.
Dyspnoea (86.7%)
Fever (58.8%)
Right ventricular failure (42.6%)
Withdrawal symptoms (25.1%)
Peripheral suppurative infection (8.8%)
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Fig. 1. Clinical presentation of patients with infective endocarditis due to intravenous nyaope use.
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antimicrobials and were culture-negative at discharge. Three patients 
presented with recurrent endocarditis. All the patients who died 
were HIV-positive. There was no statistically significant difference 
in in-hospital mortality between HIV-positive and HIV-negative 
patients (p=0.06). The most important predictors that showed a trend 
in favour of increased in-hospital mortality on univariate analysis 
were S. aureus (odds ratio (OR) 3.5; p=0.06) and Enterococcus faecalis 
infection (OR 4.6; p=0.07), and age ≥30 years (OR 3.7; p=0.05). 
A CD4+ count >200 cells/µL was a poor predictor of in-hospital 
mortality (OR 0.2; p=0.06). Interestingly, variables such as PASP 
≥35 mmHg (OR 0.3; p=0.1), vegetation size ≥10 mm (OR 0.5; p=0.4) 
and severe TR (OR 1.5; p=0.5) were not predictors of in-hospital 
mortality in this case series. On multivariate logistic regression 
analysis, S. aureus (OR 5.0; p=0.04) emerged as an important 
predictor of mortality when adjusted for PASP ≥35 mmHg, RVS' and 
age ≥30 years (Table 2).
Discussion
This study represents the first case series reported on IE secondary 
to IV nyaope use in sub-Saharan Africa. The important findings of 
this study are as follows: (i) IE due to IV nyaope use is on the rise 
in a young, predominantly male population, most of whom present 
late because of delay on the part of the patient, late referral and 
misdiagnosis; (ii) hepatitis C co-infection and immunosuppression 
due to HIV were common findings in this group; (iii) methicillin-
sensitive S. aureus (MSSA) was the most common organism cultured 
and was associated with increased in-hospital mortality; E. faecalis, 
although less prevalent, showed a tendency towards increased 
in-hospital mortality; (iv) pulmonary hypertension, vegetation size 
and severe TR were poor predictors of in-hospital mortality; (v) older 
age was associated with a trend towards increased mortality; and (vi) 
the surgical referral rate of patients with predominantly right-sided 
IE (RSIE) was very low.
We reported the first three cases of endocarditis associated with 
IV nyaope use in 2014.[2] Since then we have noted a dramatic 
rise. Because of the social stigma associated with drug abuse and 
addiction to the drug, most of the patients in this case series 
presented late to the hospital. Lack of awareness among healthcare 
professionals about IE associated with IDU was one of the factors 
resulting in late referral from peripheral hospitals, as most of the 
patients in this study were erroneously treated for more commonly 
encountered conditions such as PTB and pneumonia, especially 
in the context of HIV. This resulted in problems such as partially 
treated endocarditis and recurrence, complications related to IE 
such as septic emboli, sterile blood cultures, delayed specialist 
referral, and ultimately suboptimal management. The reasons for 
delayed diagnosis include application of Dukes criteria for the 
diagnosis of RSIE, which may not be applicable, as the sensitivity 
and specificity of the modified Dukes criteria in RSIE has not been 
studied.[5] In the context of RSIE, inclusion of septic pulmonary 
infarcts as a minor criterion in the modified Dukes criteria may 
therefore be inappropriate and these should rather form part of the 
major criteria.
Consistent with other recent studies, hepatitis C co-infection 
was common in this group of patients.[6,7] Hepatitis C co-infection 
poses numerous problems; in addition to long-term risks such as 
liver cirrhosis and cancer, and transmission of infection to others, 
it also presents ethical dilemmas with regard to surgery in IDUs. [8,9] 
In addition, significant costs are associated with the treatment 
of hepatitis C infection, often in non-compliant patients, who 
frequently have other concurrent opportunistic infections associated 
with HIV.[10]
In agreement with previous literature on IE in IDUs, the majority 
of the patients in this study were HIV-positive.[11] The difference 
between the mortality rate in our HIV-positive patients and those 
who were HIV-negative was not statistically significant. This 
finding is consistent with the study on IV drug users by Ribera 
et al.[11] In addition, in an SA study no difference in clinical and 
echocardiographic characteristics was noted between HIV-positive 
and HIV-negative patients with IE; however, none of them was noted 
to have a history of IDU.[12] The lower mortality in HIV-positive 
compared with HIV-negative patients in the current study may partly 
be due to a smaller HIV-negative sample, and also to the fact that the 
majority had a CD4+ count >200 cells/µL. Furthermore, as expected 
in HIV-infected patients, a higher CD4+ count was associated with 
a lower in-hospital mortality rate, in agreement with findings from 
previous studies.[5]
Similar to other studies in HIV-infected IV drug users, S. aureus 
was the most common pathogen in this study.[13] In contrast to 
the developed world, where methicillin-resistant S. aureus is an 
important causal pathogen of IE, MSSA is still the most prevalent 
organism associated with IE in IDUs in our setting. This is probably 
due to the early stage of the occurrence of this disease in SA, highly 
resistant organisms due to injudicious use of antibiotics not yet having 
emerged.[14] Mortality rates of 8 - 12% associated with S.  aureus IE 
in IDUs are reported in the literature.[15] In the current case series 
Fig. 2. Multiple areas of consolidation suggesting infarction due to septic 
pulmonary emboli and dilated right heart chambers on a computed 
tomography scan of the chest.
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Fever (58.8%)
Right ventricular failure (42.6%)
Withdrawal symptoms (25.1%)
Peripheral suppurative infection (8.8%)
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Fig. 3. Causative organisms in patients with infective endocarditis due to 
intra venous nyaope use.
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with predominantly RSIE, mortality was 
higher than generally reported. In contrast 
to the study by Asgeirsson et al.,[15] we 
noted increased in-hospital mortality due 
to S. aureus associated with IDU.[15] They 
reported an in-hospital mortality rate of 
2.5%, compared with 14.7% in our case 
series. The reason for our higher in-hospital 
mortality was probably delayed presentation 
and suboptimal care of these patients prior 
to referral to a tertiary care centre.
We found Enterococcus IE to be less 
common than MSSA, but a trend towards 
increased in-hospital mortality was associ-
ated with this organism. The association 
with high mortality due to Enterococcus 
endocarditis has been noted in previous 
studies.[16-18] Because of the aggressive 
nature of IE associated with Enterococcus 
and S. aureus in our setting, initial empirical 
antibiotic therapy should cover both these 
organisms.
PHT as a result of septic emboli of the 
lungs was frequent in our series, but in 
contrast to the study by Mi et al.[19] was not 
an important cause of in-hospital mortality. 
This may be due to severe RV systolic 
dysfunction and equalisation of pressure 
gradients between the right atrium and 
the RV, resulting in low-pressure TR and 
therefore lower PASP in our patients who 
died. In contrast, patients who survived 
hospital admission probably had greater RV 
systolic reserves and were therefore able to 
generate higher RV systolic pressures and 
therefore higher pressure gradients, resulting 
in severe TR in this group.
In contrast to other studies, a large 
vegetation size was a poor predictor of 
mortality in this study.[20] Although the 
majority of our patients had a vegetation size 
>10 mm, when compared with a vegetation 
size <10  mm, large vegetation size was not 
associated with in-hospital mortality. This 
is probably because a significant portion of 
the vegetation had probably embolised to 
the lungs in patients with small vegetations 
on presentation, compared with those with 
larger vegetations.
We found that older age was associated 
with a trend towards increased in-hospital 
mortality. This was probably due to longer 
duration of drug use by individuals >30 years 
of age and therefore more complications 
(such as greater lung destruction due to 
chronic embolisation and comorbidities) on 
hospital admission.
Referral for surgery was low in our series, 
as the majority of patients responded to 
antimicrobial therapy or refused surgery. 
TV valvulectomy, nowadays generally 
consi dered of historical interest only, was 
performed in 1 case, as this patient had 
a long history of drug abuse and a high 
probability of recurrent endocarditis due to 
resumption of IDU. He was discharged and 
was lost to follow-up. Another 3 patients 
underwent valve replacement and remained 
well on follow-up. None of these 4 patients 
underwent valve repair, as the valves were 
significantly destroyed. Whether surgery 
should be performed in IDUs has been 
a subject of debate, and it is our opinion 
that this decision must be individualised, 
especially in a resource-limited setting. 
According to the limited available literature, 
surgery should be offered for the first episode 
of IE in IDUs who are willing to undergo 
rehabilitation. If the patient presents with a 
second episode of IE secondary to lack of 
compliance, he or she should probably not 
qualify for further surgical intervention.[21]
Table 2. Possible predictors for mortality among hospitalised intravenous nyaope users
Variables
Univariate Multivariate
OR (95% CI) p-value OR (95% CI) p-value
Age ≥30 years 3.7 (0.95 - 14.7) 0.06 4.13 (0.89 - 19.17) 0.07
Staphylococcus aureus 3.5 (0.07 - 1.1) 0.06 5.07 (1.06 - 24.2) 0.04
PASP ≥35 mmHg 0.34 (0.09 - 1.2) 0.11 0.25 (0.05 - 1.19) 0.08
RVS' tissue Doppler velocity (cm/s) 0.5 (0.09 - 3.17) 0.17 0.39 (0.05 - 2.81) 0.35
OR = odds ratio; CI = confidence interval; PASP = pulmonary artery systolic pressure; RVS' = right ventricular systolic function.
Fig. 5. Echocardiographic images showing (A) multiple vegetations on the aortic valve complicated by a root abscess (arrows), and (B) a large vegetation on 
the tricuspid valve with extensive valve destruction (arrow).
Fig. 4. (A) Severe pulmonary hypertension (with flattened interventricular septum) due to septic 
pulmonary emboli. (B) Severe tricuspid regurgitation secondary to tricuspid valve destruction and 
pulmonary hypertension.
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Study limitations
The main limitations of this study are: (i) its retrospective design; 
(ii) its single-centre nature, which means that the results may not be 
generalisable to the larger population; and (iii) a small sample size 
and suboptimal follow-up owing to patient non-compliance.
Conclusions
We have documented the common clinical and echocardiographic 
characteristics of patients with IE secondary to IV nyaope use. IE 
due to IDU is a cause of considerable morbidity and mortality in a 
predominantly young male population. A high degree of suspicion 
must be maintained in order to make an early diagnosis and 
initiate treatment before embolic complications and heart failure 
intervene. Possible solutions include preventive education campaigns 
targeting individuals at risk of drug abuse. Early identification of 
addicted individuals and implementation of rehabilitation, cognitive-
behavioural therapy and pharmacological treatment are critical. 
Increasing awareness among healthcare workers about IE due to 
IV drug abuse through education campaigns, emphasising early 
diagnosis and treatment of IE, is also important. Lastly, establishing a 
multidisciplinary endocarditis team would facilitate optimal patient 
management and outcomes.[20]
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